LUPUS NEPHRITIS - WHO CLASS IV
Clinical trials for LUPUS NEPHRITIS - WHO CLASS IV explained in plain language.
Never miss a new study
Get alerted when new LUPUS NEPHRITIS - WHO CLASS IV trials appear
Sign up with your email to follow new studies for LUPUS NEPHRITIS - WHO CLASS IV, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take on lupus kidney disease in early trial
Disease control OngoingThis early-phase study tests a new treatment called KYV-101 for people with lupus nephritis that hasn't responded to standard therapies. KYV-101 uses a patient's own immune cells, modified to target and destroy harmful B cells that drive kidney inflammation. The study aims to che…
Matched conditions: LUPUS NEPHRITIS - WHO CLASS IV
Phase: PHASE1, PHASE2 • Sponsor: Kyverna Therapeutics • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
Immune cell therapy shows promise for tough lupus cases
Disease control OngoingThis early-stage study tests a new treatment called AB-101, made from natural killer cells, combined with antibody therapy for people with lupus nephritis or other hard-to-treat lupus. The goal is to see if it is safe and can help when standard treatments have failed. About 51 ad…
Matched conditions: LUPUS NEPHRITIS - WHO CLASS IV
Phase: PHASE1 • Sponsor: Artiva Biotherapeutics, Inc. • Aim: Disease control
Last updated May 11, 2026 20:37 UTC
-
Experimental CAR t therapy takes aim at lupus kidney disease
Disease control OngoingThis early-phase study tests a new treatment called KYV-101 for people with lupus nephritis that hasn't responded to standard therapies. The treatment uses a patient's own immune cells, modified to target and destroy harmful B cells that drive the disease. The main goals are to c…
Matched conditions: LUPUS NEPHRITIS - WHO CLASS IV
Phase: PHASE1, PHASE2 • Sponsor: Kyverna Therapeutics • Aim: Disease control
Last updated May 05, 2026 11:52 UTC